Home > About BNE > Press Room > 2010 Archive > January > Buffalo Researcher Lands $1.7M Grant

Buffalo Researcher Lands $1.7M Grant

By Tracey Drury
Thursday, January 21, 2010

A new federal grant will bring $1.7 million in research funds to the region.

Andrei Gudkov won the grant award from the National Institute for Allergies and Infectious Disease will be used to study human therapeutics targeting acute radiation syndrome.

 Gudkov is a senior vice president in basic science at Roswell Park Cancer Institute and chairman of cell stress biology in its scientific affairs department. He is also chief scientific officer at Cleveland BioLabs (NASDAQ: CBLI), which is developing Protectan CBLB502 as a drug to fight radiation toxicity.

Preliminary studies have shown CBLB502 as effective and non-toxic in mice and non-human primates, and now it is being developed into a self-administrable radiation antidote for biodefense applications.

Earlier this month, Cleveland BioLab announced it intends to respond to a Department of Defense request for proposal to develop an advanced medical radiation countermeasure, using its CBLB502 compound. The second human safety study for the drug began earlier this week.